Clinical Pharmacokinetics

, Volume 2, Issue 4, pp 312–316 | Cite as

Current Literature References on Clinical Pharmacokinetics



Digoxin Clinical Pharmacology Clinical Pharmacokinetic Antipyrine Digitoxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


Series 1

  1. Differenlial uptake of tritiated digoxin in benign and malignant central nervous system neoplasms. Williams, R.; Flanigan, S.; Bissen, J. et al.: American Journal of the Medical Sciences 272: 132 (1976).PubMedCrossRefGoogle Scholar
  2. Renal tubular handling of drugs. Cafruny, E.J.: American Journal of Medicine 62: 490 (1977).PubMedCrossRefGoogle Scholar
  3. Drug administration in renal failure. Cheigh, J.S.: American Journal of Medicine 62: 555 (1977)PubMedCrossRefGoogle Scholar
  4. Active drug metabolites and renal failure. Drayer, D.E.: American Journal of Medicine 62: 486 (1977).PubMedCrossRefGoogle Scholar
  5. Drug distribution in renal failure. Gibaldi, M.: American Journal of Medicine 62: 471 (1977).PubMedCrossRefGoogle Scholar
  6. Development of mechanisms for drug excretion. Hook, J.B. and Hewitt, W.R.: American Journal of Medicine 62: 497 (1977).PubMedCrossRefGoogle Scholar
  7. Pharmacokinetics in renal disease. Levy, G.: American Journal of Medicine 62: 461 (1977).PubMedCrossRefGoogle Scholar
  8. The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Reidenberg, M.M.: American Journal of Medicine 62: 466 (1977).PubMedCrossRefGoogle Scholar
  9. The biotransformation of drugs in renal failure. Reidenberg, M.M.: American Journal of Medicine 62: 482 (1977).PubMedCrossRefGoogle Scholar
  10. Combined seminar on the use of drugs in renal failure: narcotics, psychotherapeutic agents, antiarrhythmics, antihypertensives, sorbents, vitamin D and its analogues, anabolic hormones and nutritional supplements. Stenzel, K.H.; Reidenberg, M.M. and Rubin, A.L.: American Journal of Medicine 62: 527 (1977).CrossRefGoogle Scholar
  11. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Garver, D.L.; Dekirmenjian, H.; Davis, J.M. et al.: American Journal of Psychiatry 134: 304 (1977).PubMedGoogle Scholar
  12. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. Loughnan, P.M.; Greenwald, A.; Purton, W.W. et al.: Archives of Disease in Childhood 52: 302 (1977).PubMedCrossRefGoogle Scholar
  13. Statistic analysis of the median effective doses and plasma levels in epilepsy therapy. Oiler, L.; Laguans Hernandez, M.A.; Russi Tintore, A. et al.: Archives de Neurobiologia 40: 37 (1977).Google Scholar
  14. Fundamental and clinical studies on cefatrizine. Kawashima, S.; Kabasawa, T.; Takeda, H. et al.: Chemotherapy (Tokyo) 24: 1723 (1976).Google Scholar
  15. Fundamental and clinical studies of cefatrizine dry syrup in children. Kobayashi, Y.; Morikawa, Y. and Haruia, T.: Chemotherapy (Tokyo) 24: 1836 (1976).Google Scholar
  16. Laboratory and clinical studies for opththalmic application of cefatrizine. Matsuu, Y.; Mishima, K.; Nakamura, S. et al.: Chemotherapy (Tokyo) 24: 1976 (1976).Google Scholar
  17. Basic and clinical studies of cefatrizine in the obstetric and gynecological fields. Takase, Z.; Shirafuji, H. and Uchida, N.: Chemotherapy (Tokyo) 24: 1937 (1976).Google Scholar
  18. The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man. Marcus, F.I.; Quinn, E.J.; Horton, H. et al.: Circulation 55: 537 (1977).PubMedCrossRefGoogle Scholar
  19. Serum level monitoring and clinical pharmacokinetics of lithium. Amdisen, A.: Clinical Pharmacokinetics 2: 73 (1977).PubMedCrossRefGoogle Scholar
  20. Protein binding of coumarin anticoagulants in disease states. Bachmann, K. and Shapiro, R.: Clinical Pharmacokinetics 2: 110 (1977).PubMedCrossRefGoogle Scholar
  21. Clinical pharmacokinetics of hypnotics. Breimar, D.D.: Clinical Pharmacokinetics 2: 93 (1977).CrossRefGoogle Scholar
  22. Monitoring gold plasma levels in rheumatoid arthritis. Lorber, A.: Clinical Pharmacokinetics 2: 127 (1977).PubMedCrossRefGoogle Scholar
  23. Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation. Odar-Cedarlof, I.: Clinical Pharmacokinetics 2: 147 (1977).CrossRefGoogle Scholar
  24. Pharmacokinetic evaluation of a patient with unusually high digoxin (D) requirements (Abstract). Flackenstein, L.; Benet, L.Z. and Thomson, P.D.: Clinical Pharmacology and Therapeutics 21: 102 (1977).Google Scholar
  25. Pharmacokinetics of d-propoxyphene in anephric patients (Abstract). Gibson, T.P.; Giacomini, K.H.; Briggs, W.A. et al.: Clinical Pharmacology and Therapeutics 21: 103 (1977).Google Scholar
  26. The effects of renal and liver disease on the disposition of clofibrate (Abstract). Gugler, R.; Kuerten, J.; Jensen, C. et al.: Clinical Pharmacology and Therapeutics 21: 106 (1977).Google Scholar
  27. Disposition of diazepam and its major metabolite desmethyl-diazepam in patients with liver disease. Klotz, U.; Antonin, K.H.; Bruegel, H. et al.: Clinical Pharmacology and Therapeutics 21: 430 (1977).PubMedGoogle Scholar
  28. Bioavailability, pharmacokinetics, and pharmacodynamics of minoxidil (M) in chronic renal failure (CRF) (Abstract). Lowenthal, D.T.; Nutterperl, R.E.; Zinne, G.: Clinical Pharmacology and Therapeutics 21: 109 (1977).Google Scholar
  29. Comparative pharmacokinetics of the vinca alkaloids in man (Abstract). Nelson, R.L.; Dyke, R.W. and Root, M.A.: Clinical Pharmacology and Therapeutics 21: 112 (1977).Google Scholar
  30. Lithium transport in red blood cells of manic depressive patients (Abstract). Pandey, G.N.; Davis, J.M.; Ostrow, D.G. et al.: Clinical Pharmacology and Therapeutics 21: 113 (1977).Google Scholar
  31. Timolol maleate (TM) pharmacokinetics in chronic renal disease (CRD) (Abstract). Pitone, J.M.; Lowenthal, D.T.; Onesti, G. et al.: Clinical Pharmacology and Therapeutics 21: 114 (1977).Google Scholar
  32. Chocolate and breast-feeding: theobromine pharmacokinetics in nursing mothers (Abstract). Resman, B.H.; Blumenthal, H.P. and Jusko, W.J.: Clinical Pharmacology and Therapeutics 21: 115 (1977).Google Scholar
  33. Plasma levels of chlorpromazine: Effect of age, chronicity of disease, and duration of treatment (Abstract). Rivera-Calimlim, L.; Nasrallah, H.; Gift, T. et al.: Clinical Pharmacology and Therapeutics 21: 115 (1977).Google Scholar
  34. Increased steady-state plasma levels and prolonged half-lives of tricyclic antidepressants in the elderly (Abstract). Robinson, D.S. and Nies, A.: Clinical Pharmacology and Therapeutics 21: 116 (1977).Google Scholar
  35. Vitamin K pharmacokinetics: Response in young and elderly patients (Abstract). Shepherd, A.M.M.; Wilson, N.M. and Stevenson, I.H.: Clinical Pharmacology and Therapeutics 21: 117 (1977).Google Scholar
  36. Rate and effect of debrisoquin in hypertensive patients (Abstract). Silas, J.H.; Lennard, M.S.; Smith, A.J. et al.: Clinical Pharmacology and Therapeutics 21: 117 (1977).Google Scholar
  37. Correlation of the blood and salivary levels of the beta-one blocker metoprolol (GP-2175) (Abstract). Wan, S.K. and Maronde, R.F.: Clinical Pharmacology and Therapeutics 21: 122 (1977).Google Scholar
  38. On the serum concentration and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine sidechain sulfone in chronic psychotic patients. Axelsson, R.: Current Therapeutic Research 21: 587 (1977).Google Scholar
  39. The concentration pattern of nonconjugated thioridazine metabolites in serum by thioridazine treatment and its relationship to physiological and clinical variables. Axelsson, R. and Martensson, E.: Current Therapeutic Research 21: 561 (1977).Google Scholar
  40. Pharmacokinetics and dosage of sulklomic and sulfamerazin in patients with a restricted renal function. Stein, G. and Traeger, A.: Deutsche Gesundheitawesen 32: 605 (1977).Google Scholar
  41. Phenytoin toxicity due to severe liver disease. Hull, R.L. and Pepping, J.: Drug Intelligence and Clinical Pharmacy 11: 57 (1977).Google Scholar
  42. Prednisone for chronic active liver disease: pharmokinetics, including conversion to prednisolone. Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Gastroenterology 72: 910 (1977).PubMedGoogle Scholar
  43. Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection. Compston, Juliet E. and Creamer, B.: Gut 18: 171 (1977).PubMedCrossRefGoogle Scholar
  44. Digoxin plasma levels: guide to effective treatment (Abstract). Danon, A.; Chen, Z. and Kaplanski, J.: Israel Journal of Medical Sciences 12: 1227 (1976).Google Scholar
  45. Tissue distribution and renal clearance of digoxin in infants (Abstract). Gorodischer, R.; Jusko, W.J. and Yaffe, S.J.: Israel Journal of Medical Sciences 12: 1228 (1976).Google Scholar
  46. Radioimmunoassay of haloperidol in human serum. Clark, B.R.; Tower, Barbara B. and Rubin, R.T.: Life Sciences 20: 319 (1977).PubMedCrossRefGoogle Scholar
  47. Pharmacokinetic and clinical aspects of glycoside therapy in cases of cardiac insufficiency. Rietbrock, N. and Kuhlmann, J.: Medizinische Klinik 72: 435 (1977).PubMedGoogle Scholar
  48. Saliva lithium levels: clinical applications. Neu, C. and DiMascio, A.: Psychopharmacology Bulletin 13: 55 (1977).PubMedGoogle Scholar
  49. Renal clearance of digoxin in young infants. Gorodischer, R.; Jusko, W.J. and Yaffe, S.J.: Research Communications in Chemical Pathology and Pharmacology 16: 363 (1977).PubMedGoogle Scholar
  50. Synovial-fluid pharmacokinetics of ketoprofen. Kennedy, A.C.: Rheumatology and Rehabilitation p.20 (1976).Google Scholar
  51. Serum levels of anticonvulsants and haemotological sequelae in black epileptics. Buchanan, N.; Bille, P.; Strickwood, B. et al.: South African Medical Journal 51: 504 (1977).PubMedGoogle Scholar
  52. Drug metabolism under pathological and abnormal physiological states in animals and man. Kato, R.: Xenobiotica 7: 25 (1977).PubMedCrossRefGoogle Scholar

Series 2

  1. Methotrexate therapy for psoriasis in elderly patients with impaired renal function. Weismann, K.: Acta Dermato-Venerologica 57: 185 (1977).Google Scholar
  2. On the absorption of proscillaridin A after single oral doses to normal and achlorhydric subjects. Andersson, K.E.; Bergdahl, B.; Bertler, A. et al.: Acta Pharmacologica et Toxicologica 40: 153 (1977).PubMedCrossRefGoogle Scholar
  3. Oxazepam disposition in uremic patients. Odar-Cederlof, I.; Vessman, J.; Alvan, G. et al.: Acta Pharmacologica et Toxicologica 40(Suppl. I): 52 (1977).PubMedGoogle Scholar
  4. Comparison of side-effects with coated lithium carbonate tablets and lithium preparations giving medium-slow and slow-release. A double-blind crossover study. Edstrom, A. and Persson, G.: Acta Psychiatrica Scandinavica 55: 153 (1977).PubMedCrossRefGoogle Scholar
  5. Lithium side-effects in relation to dose and to levels and gradients of lithium in plasma. Persson, G.: Acta Psychiatrica Scandinavica 55: 208 (1977).PubMedCrossRefGoogle Scholar
  6. Comparative clinical evaluation of lofepramine and imipramine: pharmacological aspects. Siwers, B.; Borg, S.; d’Elia, G. et al.: Acta Psychiatrica Scandinavica 55: 21 (1977).PubMedCrossRefGoogle Scholar
  7. Clozapine treatment of schizophrenic patients. Plasma concentrations and coagulation factors. Thorup, M. and Fog, R.: Acta Psychiatrica Scandinavica 55: 123 (1977).PubMedCrossRefGoogle Scholar
  8. Terminal half-lives of drugs studied in patients with hepatic diseases. Closson, R.G.: American Journal of Hospital Pharmacy 34: 520 (1977).PubMedGoogle Scholar
  9. Pharmacokinetics in drug therapy. II: application of clinical pharmacokinetics in the assessment of theophylline therapy. Floyd, R.A. and Cohen, J.L.: American Journal of Hospital Pharmacy 34: 402 (1977).PubMedGoogle Scholar
  10. Absolute bioavailability of oral theophylline. Hendeles, Leslie; Weinberger, M. and Bighley, L.: American Journal of Hospital Pharmacy 34: 525 (1977).PubMedGoogle Scholar
  11. Apparent theophylline half-life fluctuations during treatment of acute left ventricular failure. Jeane, J.W.; Chick, T.W.; Miller, D.A. et al.: American Journal of Hospital Pharmacy 34: 408 (1977).Google Scholar
  12. Plasma nortriptyline levels and ECG findings. Ziegler, V.E.; Bun Tee Co and Biggs, J.T.: Amer. J. Psychiatry 134: 441 (1977).Google Scholar
  13. Pharmacokinetics of some new aminoglycosic antibiotics: tobramycin, lividomycin, amikacin, sisomycin, in the patient with a normal renal function and in the patient with renal insufficiency, a guide for posology. Oksenhendler, G.; Leroy, A.; Humbert, G. et al.: Anesthesie Analgesie Reanimation 34: 93 (1977).Google Scholar
  14. Pharmacogenetics of drugs of importance in rheumatology. Omenn, G.A.: Arthritis and Rheumatism 20 (Suppl): 549 (1977).Google Scholar
  15. Dose finding for clinical trials of antiarrhythmic substances. Hahn, K.J.: Arzneimittel Forschung 27: 283 (1977).PubMedGoogle Scholar
  16. Preliminary observations on valproic acid kinetics in patients with epilepsy. Johannessen, S.I.: Arzneimittel-Forschung 27: 1083 (1977).PubMedGoogle Scholar
  17. Pharmacokinetic studies with valproic acid in man. Klotz, U.: Arzneimittel-Forschung 27: 1085 (1977).PubMedGoogle Scholar
  18. Dose finding for the bronchospasmolytic drugs in clinical practice. Lichterfeld, A.: Arzneimittel Forschung 27: 278 (1977).PubMedGoogle Scholar
  19. Dose finding in antibacterial chemotherapy. Metzger, K.: Arzneimittel Forschung 27: 286 (1977).PubMedGoogle Scholar
  20. Problems of dose finding sexual hormones. Neumann, F.; Elger, W.; Nishino, Y. et al.: Arzneimittel Forschung 27: 296 (1977).PubMedGoogle Scholar
  21. Example of dose finding in practice. Pharmacology of an antiarrhythmic agent. Oberdorf, A. and Raschack, M.: Arzneimittel Forschung 27: 281 (1977).PubMedGoogle Scholar
  22. Finding the effective dose of diuretics in man. Rupp, W.: Arzneimittel Forschung 27: 286 (1977).Google Scholar
  23. Psychic drugs: Predicting therapeutic effects and doses by test models with normal subjects. Taeuber, K.: Arzneimittel Forschung 27: 319 (1977).PubMedGoogle Scholar
  24. Metabolism of 14C-labelled alphaxalone in man. Strunin, I.; Strunin, J.M.; Knights, K.M. et al.: British Journal of Anaesthesia 49: 609 (1977).PubMedCrossRefGoogle Scholar
  25. An index for prescribing phenytoin in childhood. Albani, M.; Schulte, F.J. and Toseland, P.A.: British Journal of Clinical Pharmacology 4: 378 (1977).PubMedCrossRefGoogle Scholar
  26. Factors influencing the therapeutic response to gentamicin treatment in children. Ashurst, A.; Houston, I.B.; Mawer, G.E. et al.: British Journal of Clinical Pharmacology 4: 394P (1977).CrossRefGoogle Scholar
  27. Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis. Calvey, T.N. and Chan, K.: British Journal of Clinical Pharmacology 4: 404P (1977).CrossRefGoogle Scholar
  28. Digoxin prescribing in perspective. Dobbs, Sylvia M.; Rodgers, Elaine M.; Kenyon, W.I. et al.: British Journal of Clinical Pharmacology 4: 327 (1977).Google Scholar
  29. Value of liver volume measurement in the study of antipyrine kinetics in liver disease. Halliwell, M.; Homeida, M. and Roberts, C.J.C.: British Journal of Clinical Pharmacology 4: 393P (1977).CrossRefGoogle Scholar
  30. Digoxin measurements in general practice. Holt, D.W.; Williamson, J.D. and Volans, G.N.: British Journal of Clinical Pharmacology 4: 321 (1977).PubMedCrossRefGoogle Scholar
  31. The absorption and elimination of ICI 74,917 in man. Pickup, M.E.; Johnson, A.J.; May, C.S. et al.: British Journal of Clinical Pharmacology 4: 357 (1977).PubMedCrossRefGoogle Scholar
  32. Absorption kinetics of aspirin and quinine in elderly subjects. Salem, S.A.M. and Stevenson, I.M.: British Journal of Clinical Pharmacology 4: 397P (1977).CrossRefGoogle Scholar
  33. Age as a determinant of sensitivity to warfarin. Shepherd, A.M.M.; Hewick, D.S.; Moreland, T.A. et al.: British Journal of Clinical Pharmacology 4: 315 (1977).PubMedCrossRefGoogle Scholar
  34. Factors influencing antipyrine elimination. The First Lilly Prize Lecture, University of Dundee, July 1976. Stevenson, I.H.: British Journal of Clinical Pharmacology 4: 261 (1977).PubMedCrossRefGoogle Scholar
  35. Sedation in liver disease. Leading article: British Medical Journal 1: 1241 (1977).Google Scholar
  36. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. Forrest, J.A.H.; Finlayson, N.D.C.; Adjepon-Yamoah, K.K. et al.: British Medical Journal 1: 1384 (1977).PubMedCrossRefGoogle Scholar
  37. May mothers given warfarin breast-feed their infants? Orme, M.L’E.; Lewis, P.J.; De Swiet, M. et al.: British Medical Journal 1: 1564 (1977).PubMedCrossRefGoogle Scholar
  38. Phase I study of oral mitomycin C. Crooke, S.T.; Henderson, M.; Samson, M. et al.: Cancer Treatment Reports 60: 1633 (1976).PubMedGoogle Scholar
  39. Haloperidol concentrations in blood in cases of acute intoxication. Coutselinis, A.; Boukis, D. and Kentarchou, P.: Clinical Chemistry 23: 900 (1977).PubMedGoogle Scholar
  40. Influence of sex on drug kinetics in man. Giudicelli, J.F. and Tillement, J.P.: Clinical Pharmacokinetics 2: 157 (1977).PubMedCrossRefGoogle Scholar
  41. Drug kinetics in pregnancy. Krauer, Beatrice and Krauer, F.: Clinical Pharmacokinetics 2: 167 (1977).PubMedCrossRefGoogle Scholar
  42. Disease and acetylation polymorphism. Lunde, P.K.M.; Frislid, K. and Hansteen, V.; Clinical Pharmacokinetics 2: 182 (1977).PubMedCrossRefGoogle Scholar
  43. Pharmacokinetics and response to diazoxide in renal failure. Pearson, R.M.: Clinical Pharmacokinetics 2: 198 (1977).PubMedCrossRefGoogle Scholar
  44. Protein binding of cardiac glycosides in disease status. Storstein, L.: Clinical Pharmacokinetics 2: 220 (1977).PubMedCrossRefGoogle Scholar
  45. Interpretation of the serum digoxin concentration. Weintraub, M.: Clinical Pharmacokinetics 2: 205 (1977).PubMedCrossRefGoogle Scholar
  46. Relationship between blood level of atenolol and pharmacologic effect. Amery, A.; De Plaen, Jean-Francois; Lijnen, P. et al.: Clinical Pharmacology and Therapeutics 21: 691 (1977).PubMedGoogle Scholar
  47. Studies on digitalis. XII: Kinetic pattern of digitoxin metabolism in patients with biliary fistules. Storstein, L. and Amlie, J.: Clinical Pharmacology and Therapeutics 21: 659 (1977).PubMedGoogle Scholar
  48. Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. van Prooijen, R.; van der Kleijn, E. and Haanen, C.: Clinical Pharmacology and Therapeutics 21: 744 (1977).PubMedGoogle Scholar
  49. Serum levels of tobramycin in children. Da Nobrega, F.J.; De Mello, F.G.; Trabulsi, L.R. et al.: Current Therapeutic Research 21: 741 (1977).Google Scholar
  50. Pharmacokinetics of Bay g 2821 in the dog and in man. Ritter, W.: Current Medical Research and Opinion 4: 564 (1977).PubMedCrossRefGoogle Scholar
  51. Thioridazine metabolism and clinical response. A pilot study. Sakalis, G.; Traficante, L.J.; Gershon, S. et al.: Current Therapeutic Research 21: 720 (1977).Google Scholar
  52. Relationship between the antihypertensive effect and the drug plasma concentration of pindolol. Weiss, Y.A.; Loris, Y.; Safar, M.E. et al.: Current Therapeutic Research 21: 644 (1977).Google Scholar
  53. Post-mortem digoxin levels — two-unusual case reports. Dickson, S.J. and Blazey, N.D.: Forensic Science 9: 145 (1977).PubMedCrossRefGoogle Scholar
  54. Pharmacokinetics of cardiac glycosides and clinical significance. Rietbrock, N.; Kuhlmann, J. and Voehringer, H.F.: Fortschritte der Medizin 95: 909 (1977).PubMedGoogle Scholar
  55. Clinical pharmacology of cefadroxil and cephalexin, blood, urine and tissue concentrations in pregnancy at term. Fuentes-Calvo, V.R. et al.: Investigacion Medica Internacional 4: 3 (1977).Google Scholar
  56. The secretion of minocycline in sputum during therapy of bronchopulmonary infection in chronic chest diseases. Brogan, T.D.; Neale, L.; Ryley, H.C. et al.: Journal of Antimicrobial Chemotherapy 3: 247 (1977).PubMedCrossRefGoogle Scholar
  57. Warfarin elimination and responsiveness in patients with renal dysfunction. Bachmann, K.; Shapiro, D. and Mackiewicz, J.: Journal of Clinical Pharmacology 17: 292 (1977).PubMedGoogle Scholar
  58. The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma. Brooks, S.M.; Sholiton, L.P; Werk, E.E. Jr. et al.: J. Clin. Pharmacol. 308 (1977).Google Scholar
  59. Metabolic studies in patients with nadolol: oral and intravenous administration. Dreyfuss, J.; Brannick, L.J.; Vukovich, R.A. et al.: Journal of Clinical Pharmacology 17: 300 (1977).PubMedGoogle Scholar
  60. Maternal-fetal pharmacology activity of amikacin. Bernard, Betty; Abate, Micheline; Thielen, P.F. et al.: Journal of Infectious Diseases 135: 925 (1977).PubMedCrossRefGoogle Scholar
  61. Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness. Hall, W.H.; Gerding, Dale N. and Schierl, Elizabeth A.: Journal of Infectious Diseases 135: 957 (1977).PubMedCrossRefGoogle Scholar
  62. Comparison of concentrations of amoxicillin and ampicillin in serum and middle ear fluid of children with chronic otitis media. Klimek, J.J.; Nightingale, C; Lehmann, W.B. et al.: Journal of Infectious Diseases 135: 999 (1977).PubMedCrossRefGoogle Scholar
  63. Pharmacokinetics of methicillin in patients with cystic fibrosis. Yaffe, S.J.; Gerbracht, L.M.; Mosovich, L.L. et al.: Journal of Infectious Diseases 135: 828 (1977).PubMedCrossRefGoogle Scholar
  64. Clinical pharmacology of methicillin in neonates. Sarff, L.D.; McCracken, G.H.; Thomas, Marion L. et al.: Journal of Pediatrics 90: 1005 (1977).PubMedCrossRefGoogle Scholar
  65. Digitalis pharmacokinetics and therapy with respect to impaired renal function. Kramer, P.: Klinische Wochenschrift 55: 1 (1977).PubMedCrossRefGoogle Scholar
  66. Plasma digoxin levels in anuric patients and normal subjects taking digitoxin. Kramer, P.; Langescheid, G; Saul, J. et al.: Klinische Wochenschrift 55: 245 (1977).PubMedCrossRefGoogle Scholar
  67. Plasma concentrations after injection or infusion of phenytoin. Schmidt, D. and Vogel, A.: Klinische Wochenschrift 55: 219 (1977).PubMedCrossRefGoogle Scholar
  68. Cephalexin levels in the bronchial secretion of children. Daschner, F.: Munchener Medizinische Wochenschrift 119: 339 (1977).PubMedGoogle Scholar
  69. Plasma digoxin estimation in the newborn. Berdeaux, A.; Batisse, A.; Richer, Ch. et al: La Nouvelle Presse Medicale 6: 2142 (1977).PubMedGoogle Scholar
  70. Value of the estimation of anticonvulsants in the treatment of epilepsy. Loiseau, P.; Brachet-Liermam, A.; Legroux, M. et al: La Nouvelle Presse Medicale 6: 813 (1977).PubMedGoogle Scholar
  71. Relationship between anti-hypertensive action and plasma concentration of pindolol. Weiss, Y.; Lona, Y.; Lavene, D. et al: La Nouvelle Presse Medicale 6: 927 (1977).PubMedGoogle Scholar
  72. Placenlal transfer and metabolism of beta-methasone in human pregnancy. Anderson, Anne B.M.; Gennser G.; Jeremy, J.Y. et al: Obstetrics and Gynecology 49: 471 (1977).PubMedGoogle Scholar
  73. Amikacin pharmacokinetics in the therapy of childhood urinary tract infections. Khan, A.J.; Evans, H.E.; Jhaven, R. et al: Pediatrics 58: 873 (1976).PubMedGoogle Scholar
  74. Serum concentration and serum half-life of digoxin in premature and mature newborns. Lang, D. and von Bernuth, G.: Pediatrics 59: 902 (1977).PubMedGoogle Scholar
  75. Clinical pharmacology of anaesthetic agents and anaesthetic adjuvants in renal insufficiency. Stoeckel, H.: Praktische Anaethesie Wiederbelebung und Intensivtherapie 12: 97 (1977).Google Scholar
  76. Plasma nortnptyline and clinical response — a study using changing plasma levels. Burrows, G.D.; Maguire, K.P.; Scoggins, B.A. et al: Psychological Medicine 7: 87 (1977).PubMedCrossRefGoogle Scholar
  77. Concentrations of oxyteiracycline, tetracycline and doxycycline in mandibular osteitis. Bystedt, N.; Dornbusch, K. and Nord, C.E.: Scandinavian Journal of Infectious Diseases p 37 (1976).Google Scholar
  78. Concentration of doxycycline in bowel tissue and postoperative infections. Hoejer, H. and Wettcrfors, J.: Scandinavian Journal of Infectious Diseases Suppl No 9: 100 (1976).Google Scholar
  79. The elimination of tritiated doxycychne in normal subjects and in patients with severely impaired renal function. Mahon, W.A.; Johnson, G.E.; Endrenyi, L. et al.: Scandinavian Journal of Infectious Diseases Suppl No 9: 24 (1976).Google Scholar
  80. The concentration of doxycychne in human prostate gland and its role in the treatment of prostitis. Oosterlinck, W.; Wallijn, E. and Wijndaele, J.J.: Scandinavian Journal of Infectious Diseases Suppl No 9: 85 (1976).Google Scholar
  81. The hazards of drug prescription in patients with liver cirrhosis. Caulin, C.; Wagner, J.C. and Lamotte, M.: Semaine des Hopitaux Therapeutique 53: 109 (1977).PubMedGoogle Scholar
  82. Raised serum transaminase levels in patients with rheumatic fever treated with salicylates. Gitlin, N. and Grant, J.: South African Medical Journal 51: 697 (1977).PubMedGoogle Scholar
  83. The influence of biliary disease on the excretion of cefazohn in human bile. McLeish, A. E.; Strachan, C.J.L.; Powis, S.J.A. et al: Surgery 81: 426 (1977).PubMedGoogle Scholar
  84. Phenformin blood levels on usual therapeutic dosage. Catellier, C.; Fraser, E. and Ayotte-Ferron, L.: L’Union Medicale du Canada 106: 323 (1977).PubMedGoogle Scholar
  85. Comparative studies of placental diffusion of propanidid (sombrevin) and barbiturate in premature and caesanar births. Yarga, J.; Kiszel, J.; Csomor, S.; Balazsvargo, N. et al: Zentralblatt fur Gynaekologie 99: 343 (1977).Google Scholar

Copyright information

© ADIS Press 1977

Personalised recommendations